undamentalytics Newsletter
Sign in

Omnicell, Inc. (OMCL) stock

Add to watchlist

Add holding +

NASDAQ: OMCL Nasdaq Health Care Technology Next results ~February 4, 2027

B Fundamentals grade

Omnicell, Inc. is a US-listed company in the health care technology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$44

Cash-flow model

Base case. Range ~$33–$57 across our lower- and higher-growth cases (-0.6%–9.4% a year).

Price vs value

Modestly undervalued

The price is inside our value range, 17% below our base value.

Price used: $36.41, November 2, 2026

Omnicell, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 11 sales by directors and officers, last 12 monthsInsider trades
  • Funds169 adding, 109 cuttingOf 51 active managers that changed their stake, 28 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Omnicell files

Where Omnicell stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.25bn, up 8.5% on a year earlier, faster than the 7.9% growth a quarter earlier. Free-cash-flow margin rose to 11.4% from 9.3% a year earlier. Operating margin widened to 4.6% from 1.3%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 6 of our 7 financial-health checks. Our cash-flow model value is $44.33 a share, against a share price of $37.33. At that price, our model says the market is pricing in about 1.0% a year of cash-flow growth for five years, close to the 1.9% a year revenue growth it has delivered.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~February 4, 2027 (estimated)

Omnicell, Inc.'s trailing-twelve-month revenue grew 8.5% year on year, with a free-cash-flow margin of 11.4%.

Our discounted-cash-flow model values the business at ~$44 per share in the base case (~$33–$57 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 33.5% while net income grew 69.3%: a 36pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Priced below our value. The share price of $36.41 is 20% below our value per share of $44.
  • Margins widening. Operating margin is up 3.3 points on a year ago.
  • Shrinking share count. Diluted shares fell 1.5% in a year, so each share owns more of the business.

Things to watch

  • High earnings multiple. The shares trade at 43 times the last 12 months' earnings, so expectations are demanding.
  • Volatile shares. Over the past year the shares showed annualised volatility of 48% and a beta of 1.1 against the S&P 500.
  • Estimates being cut. Analysts' consensus for next year's earnings per share has fallen 5.9% over 90 days.
  • Earnings expected to fall. The consensus expects earnings per share to fall 18% next year.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$0.58 against an average estimate of $0.42: beat by 38.9%
Revenue
$312m, up 7.4% on a year earlier
Share reaction
+1.9% in the first session after the results on October 29, 2026, against -2.1% for the S&P 500
Next report
October 29, 2026; average EPS estimate $0.42

Omnicell's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.7%
  • 1 week-1.5%
  • 1 month+8.4%
  • This year-19.6%
  • 1 year+8.5%
  • 5 years-79.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.2B
Operating margin
4.6%
Net margin
3.1%
EPS (TTM, diluted)
$0.85

Growth

Revenue growth
+8.5%
Change in growth rate
+0.6 pts
Share count change
−1.5%

Cash

Free cash flow (TTM)
$143M
FCF margin
11.4%
Stock pay % of revenue
3.6%

Earnings

Last results
October 29, 2026
Next results (est.)
February 4, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Results
  3. Announcement
  4. Results
  5. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Omnicell, Inc. valuation models and calculator

What the price is pricing in

The share price implies about 0.3% a year of cash-flow growth for five years.That is close to the 1.9% a year revenue growth Omnicell has delivered.

  • Priced in0.3%
  • Last 12 months8.5%
  • 3 years a year0.3%
  • 5 years a year1.9%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($36.20, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Hold12-month view
12-month price target
~$44
Price used
$36.20close November 3, 2026
Implied change
▲ +21%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Omnicell, Inc.'s free cash flow after stock-based pay with after-tax interest added back ($101M, FY2026 Q2 TTM), growing 1.8% and 3.9% in the next two years (forecasts, guidance and its record), then back to 4.4% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$33–~$57 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Omnicell, Inc.'s free cash flow after stock-based pay ( $101M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Omnicell, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.04 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$44 ~$33–$57 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$24 ~$18–$43 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$6.8 ~$4.0–$11 Left out: out of range vs price (0.19x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity below long-run growth
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$37 ~$24–$44 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Omnicell, Inc. with Health Care Technology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −24%
  • Revenue growth 5 points higher ▲ +31%
  • Free-cash-flow margin 1 point lower ▼ −8%
  • Last year's free-cash-flow margin change, if it persists ▲ +22%
  • Discount rate 1 point higher ▼ −14%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $35$46$61$81$108$141
8.5% $27$36$47$61$79$103
10% $23$29$38$49$63$81

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$31.08$33.90$48.50$61.24$81.72$120.02$180.44$50.42$37.63$44.52$45.30$36.41
Market value$1.1bn$1.2bn$1.9bn$2.5bn$3.5bn$5.3bn$8.7bn$2.3bn$1.7bn$2.1bn$2.1bn$1.7bn
+ Net debt (− = net cash)−$82m$200m$178m$73m−$77m−$19m$139m$236m$102m−$28m−$29m−$124m
Enterprise value$1.1bn$1.4bn$2.1bn$2.6bn$3.4bn$5.2bn$8.8bn$2.6bn$1.8bn$2.0bn$2.1bn$1.6bn
Multiples
Price / sales 2.4x1.8x2.6x3.2x3.9x5.9x7.6x1.8x1.5x1.9x1.8x1.3x
Price / earnings 37.1x128.1x61.5x65.8x57.2x163.1x111.1xn/m—164.3xn/m42.9x
Price / free cash flow 36.9x34.3x197.8x30.9x27.2x32.2x42.6x76.5x12.2x13.6x24.2x11.8x
EV / EBITDA 14.3x18.2x32.8x26.7x26.0x54.2x54.1x30.1x34.4x24.6x24.7x11.5x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

50 /100

Moderate moat

How hard Omnicell's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 10 / 20

    Cash operating profit has been a median 8.5% of total assets over 8 years.

  • Pricing power 15 / 20

    Gross margin has been a median 45.6%, moving by 2.3 percentage points (standard deviation) across 10 years.

  • Durability 0 / 20

    Operating margin has been a median 4.7%; its worst year was -3.5%.

  • Cash conversion 16 / 20

    Free cash flow was positive in 10 of 10 years, at a median 11.4% of revenue.

  • Discipline 14 / 20

    The diluted share count rose 1.1% over five years; stock-based pay has been a median 4.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (55 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $2.49 +54% $1.2bn +4%
Next $2.04 −18% $1.3bn +3%

Next year's EPS estimate has moved −5.9% in 90 days, across 8 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +6.9% on 90 days ago. In the last 30 days, 6 analysts raised Omnicell, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Omnicell, Inc., last 90 days
$2.00 $2.20 $2.40 $2.60 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $2.33 Current fiscal year, 60 days ago: $2.28 Current fiscal year, 30 days ago: $2.28 Current fiscal year, 7 days ago: $2.28 Current fiscal year, Now: $2.49 $2.49 Next fiscal year, 90 days ago: $2.16 Next fiscal year, 60 days ago: $2.09 Next fiscal year, 30 days ago: $2.09 Next fiscal year, 7 days ago: $2.06 Next fiscal year, Now: $2.04 $2.04

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $2.33$2.16
60 days ago $2.28$2.09
30 days ago $2.28$2.09
7 days ago $2.28$2.06
Now $2.49$2.04

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.42 $0.58 +38.9%
Jun 2026 $0.47 $0.94 +101.1%
Mar 2026 $0.33 $0.55 +66.0%
Dec 2025 $0.50 $0.40 −19.4%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows Omnicell, Inc.'s revenue by +1.8% next year and +3.9% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+0.1%, weight 60%) and the company's own record (+4.4%, weight 40%) . How the weights are set.

Analyst recommendations

8 analysts, Oct 2026
Buy788%
Hold113%
Sell00%

Monthly trend

  1. Oct 20261618
  2. Sep 20261618
  3. Aug 20261618
  4. Jul 20261618

Counts of recommendations published by analysts covering Omnicell, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.7%
of tradable shares
Days to cover
6.58
at average volume
Short interest, 1 month
−1%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
2.1%
of shares
Employees
3,580
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +8.5%

$33.57 on October 31, 2025 to $36.41

ThenNowEffect
Revenue (last 12 months) $1.1bn $1.2bn +8.5%
Net margin 2.0% 3.1% +56.1%
P/E multiple 67.9x 42.9x −36.9%
Share count 47m 46m +1.5%

Biggest factor: p/e multiple.

Last 3 years +19.6%

$30.44 on November 3, 2023 to $36.41

ThenNowEffect
Revenue (last 12 months) $1.2bn $1.2bn +0.9%
P/S multiple 1.1x 1.3x +21.4%
Share count 45m 46m −2.4%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
OMCL+50%−72%−25%+18%+2%−20%
Industry peers (median)−14%−60%−16%−24%−28%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
OMCL58%25%50%42%50%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
OMCL−10%−74%−62%−32%−46%−37%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 87% from November 23, 2021 to May 7, 2025. Getting back needed a 646% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$32.23 – $51.39
From 52-week high
−29.1%
vs 50-day average
+5.2%
vs 200-day average
−6.5%
Volatility (1 year)
49%
Beta vs S&P 500
1.05

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±14.7%
After a week
6 up, 5 down
typical move ±17.0%
After a month
7 up, 4 down
typical move ±18.5%
Results releasedNext dayS&P 500 next day5 days21 days
October 29, 2026 +1.9% −2.1% — —
July 30, 2026 −14.6% +2.4% −12.7% −20.1%
April 28, 2026 +14.5% −0.5% +15.8% +18.8%
February 5, 2026 −20.6% +0.6% −22.5% −14.7%
October 30, 2025 +13.5% −0.8% +20.9% +22.2%
July 31, 2025 +0.2% −2.0% +4.5% +9.7%
May 6, 2025 −19.2% −0.4% −8.2% +1.2%
February 6, 2025 −9.5% −0.6% −9.4% −19.0%
October 30, 2024 +21.2% −2.3% +30.9% +16.1%
August 1, 2024 +34.3% −3.3% +37.6% +52.3%
May 2, 2024 +10.9% +2.2% +11.3% +16.3%
February 8, 2024 −15.6% +0.6% −12.8% −12.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Omnicell, Inc.’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: fundamentals grade B (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Omnicell, Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Omnicell, Inc.
$1.1B $1.1B $1.2B $1.2B $1.3B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.2B Revenue (TTM), FY23 Q4: $1.1B Revenue (TTM), FY24 Q1: $1.1B Revenue (TTM), FY24 Q2: $1.1B Revenue (TTM), FY24 Q3: $1.1B Revenue (TTM), FY24 Q4: $1.1B Revenue (TTM), FY25 Q1: $1.1B Revenue (TTM), FY25 Q2: $1.1B Revenue (TTM), FY25 Q3: $1.2B Revenue (TTM), FY25 Q4: $1.2B Revenue (TTM), FY26 Q1: $1.2B Revenue (TTM), FY26 Q2: $1.2B $1.2B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.2B
FY23 Q4 $1.1B
FY24 Q1 $1.1B
FY24 Q2 $1.1B
FY24 Q3 $1.1B
FY24 Q4 $1.1B
FY25 Q1 $1.1B
FY25 Q2 $1.1B
FY25 Q3 $1.2B
FY25 Q4 $1.2B
FY26 Q1 $1.2B
FY26 Q2 $1.2B
Revenue growth, TTM YoY Omnicell, Inc.
-20% -10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -9.4% Revenue growth, TTM YoY, FY23 Q4: -11.5% Revenue growth, TTM YoY, FY24 Q1: -13.0% Revenue growth, TTM YoY, FY24 Q2: -12.5% Revenue growth, TTM YoY, FY24 Q3: -10.3% Revenue growth, TTM YoY, FY24 Q4: -3.0% Revenue growth, TTM YoY, FY25 Q1: 3.0% Revenue growth, TTM YoY, FY25 Q2: 6.4% Revenue growth, TTM YoY, FY25 Q3: 10.7% Revenue growth, TTM YoY, FY25 Q4: 6.5% Revenue growth, TTM YoY, FY26 Q1: 7.9% Revenue growth, TTM YoY, FY26 Q2: 8.5% 8.5%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -9.4%
FY23 Q4 -11.5%
FY24 Q1 -13.0%
FY24 Q2 -12.5%
FY24 Q3 -10.3%
FY24 Q4 -3.0%
FY25 Q1 3.0%
FY25 Q2 6.4%
FY25 Q3 10.7%
FY25 Q4 6.5%
FY26 Q1 7.9%
FY26 Q2 8.5%
Operating margin (TTM) Omnicell, Inc.
-5% 0% 5% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -4.2% Operating margin (TTM), FY23 Q4: -3.0% Operating margin (TTM), FY24 Q1: -3.1% Operating margin (TTM), FY24 Q2: -3.5% Operating margin (TTM), FY24 Q3: -3.3% Operating margin (TTM), FY24 Q4: 0.0% Operating margin (TTM), FY25 Q1: 0.9% Operating margin (TTM), FY25 Q2: 1.3% Operating margin (TTM), FY25 Q3: 1.5% Operating margin (TTM), FY25 Q4: 0.4% Operating margin (TTM), FY26 Q1: 2.7% Operating margin (TTM), FY26 Q2: 4.6% 4.6%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -4.2%
FY23 Q4 -3.0%
FY24 Q1 -3.1%
FY24 Q2 -3.5%
FY24 Q3 -3.3%
FY24 Q4 0.0%
FY25 Q1 0.9%
FY25 Q2 1.3%
FY25 Q3 1.5%
FY25 Q4 0.4%
FY26 Q1 2.7%
FY26 Q2 4.6%
FCF margin (TTM) Omnicell, Inc.
5% 10% 15% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 15.1% FCF margin (TTM), FY23 Q4: 12.2% FCF margin (TTM), FY24 Q1: 16.1% FCF margin (TTM), FY24 Q2: 15.4% FCF margin (TTM), FY24 Q3: 12.5% FCF margin (TTM), FY24 Q4: 13.6% FCF margin (TTM), FY25 Q1: 11.0% FCF margin (TTM), FY25 Q2: 9.3% FCF margin (TTM), FY25 Q3: 9.5% FCF margin (TTM), FY25 Q4: 7.3% FCF margin (TTM), FY26 Q1: 9.3% FCF margin (TTM), FY26 Q2: 11.4% 11.4%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 15.1%
FY23 Q4 12.2%
FY24 Q1 16.1%
FY24 Q2 15.4%
FY24 Q3 12.5%
FY24 Q4 13.6%
FY25 Q1 11.0%
FY25 Q2 9.3%
FY25 Q3 9.5%
FY25 Q4 7.3%
FY26 Q1 9.3%
FY26 Q2 11.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 213 222 246 314 381 441 485 696 713 787 897 892 1,132 1,296 1,147 1,112 1,185 1,247
Gross profit 105 118 136 171 203 234 248 317 319 372 437 413 555 589 497 471 503 558
EBITDA 10 18 24 40 54 70 74 80 63 96 132 97 162 85 52 83 84 135
Operating income 1 10 16 27 35 50 49 21 11 44 78 36 90 −2 −35 0 5 58
Net income 0 5 10 16 24 31 31 10 31 38 61 32 78 6 −20 13 2 39
Diluted EPS $0.01 $0.15 $0.30 $0.47 $0.67 $0.83 $0.84 $0.26 $0.79 $0.93 $1.43 $0.74 $1.62 $0.12 −$0.45 $0.27 $0.04 $0.85
Growth (year on year)
Revenue — +4.2% +10.4% +27.9% +21.2% +15.8% +9.9% +43.6% +2.4% +10.5% +13.9% −0.5% +26.9% +14.5% −11.5% −3.0% +6.5% +8.5%
EBITDA — +79.7% +33.4% +67.1% +32.7% +30.2% +6.3% +7.4% −21.5% +52.8% +37.8% −26.8% +68.2% −47.9% −38.0% +57.4% +1.7% +41.3%
Operating income — — +70.3% +67.2% +30.1% +40.5% −1.9% −56.0% −47.9% — +76.5% −54.7% +151.9% −102.6% — — — —
Net income — — +112.4% +55.7% +48.2% +27.3% +0.8% −68.3% — +23.6% +62.6% −47.5% +141.8% −92.7% — — — +69.3%
Diluted EPS — — +100.0% +56.7% +42.6% +23.9% +1.2% −69.0% — +17.7% +53.8% −48.3% +118.9% −92.6% — — — +71.8%
Margins
Gross margin 49.3% 53.0% 55.3% 54.3% 53.4% 53.0% 51.2% 45.6% 44.7% 47.3% 48.7% 46.3% 49.0% 45.4% 43.3% 42.3% 42.5% 44.8%
EBITDA margin 4.7% 8.2% 9.9% 12.9% 14.1% 15.8% 15.3% 11.5% 8.8% 12.2% 14.7% 10.8% 14.4% 6.5% 4.6% 7.4% 7.1% 10.8%
Operating margin 0.3% 4.3% 6.6% 8.6% 9.3% 11.2% 10.0% 3.1% 1.6% 5.6% 8.7% 4.0% 7.9% −0.2% −3.0% 0.0% 0.4% 4.6%
Net margin 0.2% 2.2% 4.2% 5.2% 6.3% 6.9% 6.3% 1.4% 4.3% 4.8% 6.8% 3.6% 6.9% 0.4% −1.8% 1.1% 0.2% 3.1%
Free-cash-flow margin 20.0% 6.2% 9.2% 7.8% 11.3% 12.1% 6.4% 5.2% 1.3% 10.2% 14.4% 18.3% 17.9% 2.3% 12.2% 13.6% 7.3% 11.4%
Cash flow
Cash from operations 46 21 31 39 55 65 38 50 25 104 145 186 232 78 181 188 127 181
Capital spending 4 7 9 15 12 12 8 13 15 24 16 23 29 48 41 36 40 39
Free cash flow 43 14 23 24 43 53 31 36 9 80 129 163 203 30 140 151 87 143
Stock-based pay 10 9 9 9 11 13 15 20 22 29 34 45 53 68 55 39 45 45
Free cash flow after stock pay 33 5 13 15 32 40 16 17 −12 51 95 118 150 −38 84 112 42 98
Balance sheet
Cash 169 176 192 62 105 126 82 54 32 67 127 486 349 330 468 369 197 292
Total debt 0 0 0 0 0 0 0 254 210 140 50 467 488 567 570 341 168 168
Net debt (negative = net cash) −169 −176 −192 −62 −105 −126 −82 200 178 73 −77 −19 139 236 102 −28 −29 −124
Diluted shares 32m 34m 34m 34m 36m 37m 37m 37m 39m 41m 43m 44m 48m 46m 45m 46m 46m 46m
Returned to shareholders
Buybacks — 0 13 12 21 24 50 0 0 0 0 53 0 52 0 0 78 —
Total returned — 0 13 12 21 24 50 0 0 0 0 53 0 52 0 0 78 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 7 checks passed · June 30, 2026
What it owns · $2.0bn
Short-term assets $735mLonger-term assets $1.3bn
What it owes, and who funded it · $2.0bn
Short-term liabilities $447mLonger-term liabilities $260mShareholders' equity $1.3bn
  • Short-term assets cover short-term liabilities $735m of assets due within a year against $447m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $735m short-term assets against $260m of longer-dated liabilities.
  • More cash than debt $292m of cash against $168m of debt.
  • Debt below 40% of shareholders' equity Debt is 13% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 13% over five years.
  • A year's operating cash flow covers at least 20% of debt $181m of operating cash flow against $168m of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Omnicell, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$77.6M
Diluted share count
−1.5%
year over year
R&D spending
7.1%
of revenue
Sales & admin spending
33.0%
of revenue

Competitors: side by side with peers

Closest by revenue in health care technology
Last 12 months unless stated OMCL WAY TEM GDRX DOCS TDOC Median
Revenue, last 12 months $1.2bn $1.3bn $1.5bn $785m $656m $2.5bn $292m
Revenue growth, last 12 months 8.5% 21.4% 36.6% −1.8% 11.2% −2.4% 8.8%
Revenue growth, 3-year average 0.3% — — 1.8% 14.5% −1.5% 0.8%
Revenue growth, latest quarter 7.4% 21.2% 23.1% −1.3% 7.3% −3.4% 7.4%
Gross margin 44.8% — — — 88.1% 70.2% 58.6%
Operating margin 4.6% 21.9% −18.5% 9.5% 29.6% −6.6% −12.5%
Operating margin, 3-year average 0.8% 19.1% −49.5% 5.6% 35.4% −18.8% −18.8%
Net margin 3.1% 10.7% −12.5% 2.1% 25.5% −6.3% −12.5%
Cash from operations / revenue 14.6% 24.9% −7.2% 25.7% 46.7% 10.9% 9.7%
Free-cash-flow margin 11.4% 20.9% −9.1% 25.1% 46.7% 10.6% 9.2%
Free-cash-flow margin, 3-year average 12.0% 19.4% −21.2% 21.7% 43.6% 11.5% 8.2%
Stock pay / revenue 3.6% 4.9% 13.3% 9.7% 20.8% 2.1% 9.5%
Change in share count −1.5% 9.7% — −9.8% −2.5% 2.9% 2.9%

Median of all 23 companies we cover in health care technology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

23 health care technology companies
Measure Company Peer median Rank
Revenue growth Growth 8.5% 8.8% 13 of 23
Change in growth rate Growth +0.6pp -0.3pp 10 of 23
Gross margin Profitability 44.8% 58.2% 9 of 14
Operating margin Profitability 4.6% -6.6% 9 of 22
Net margin Profitability 3.1% -12.5% 8 of 23
Free-cash-flow margin Cash generation 11.4% 10.6% 10 of 22
Stock pay as % of revenue Cash generation 3.6% 9.7% 6 of 22
Long-term debt as % of assets Balance sheet 8.4% 20.1% 4 of 15
Change in share count Balance sheet -1.5% 2.6% 5 of 19

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $666M 56.2% ▲ 5.6%
Connected Devices Software Licenses and Other $565M 84.9% ▲ 4.9%
Consumables $100M 15.1% ▲ 9.7%
Services $519M 43.8% ▲ 7.8%
Technical Services $260M 50.1% ▲ 9.2%
Saa S and Expert Services $259M 49.9% ▲ 6.4%
Geography
Region Revenue Share YoY
United States $1.1B 89.9% ▲ 5.2%
Outside the US $120M 10.1% ▲ 19.9%

From Omnicell, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2B
Institutions reporting
303
Shares held vs prior quarter
▲ 3.1%
Positions opened / closed
51 / 21

Top buyers and sellers, Q2 2026: 169 institutions bought and 109 sold ; the biggest buyer was Nuveen, LLC (+640K shares) and the biggest seller Lazard Asset Management LLC (−1.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $313M 7.5M 15.6% ▲ 4.6%
Vanguard Portfolio Management LLC $131M 3.2M 6.5% ▼ 2.0%
Wellington Management Group LLP $112M 2.7M 5.6% ▼ 0.2%
Dimensional Fund Advisors LP $102M 2.5M 5.1% ▲ 0.1%
State Street Corp $86.6M 2.1M 4.3% ▲ 6.9%
Vanguard Capital Management LLC $81.8M 2.0M 4.1% ▲ 1.9%
Millennium Management LLC $72M 1.7M 3.6% ▼ 24.2%
Nomura Asset Management International Inc. $66.7M 1.6M 3.3% ▲ 35.7%
Geode Capital Management, LLC $50.5M 1.2M 2.5% ▲ 6.5%
Nuveen, LLC $42.7M 1.0M 2.1% ▲ 164.7%
Arrowstreet Capital, Limited Partnership $37.9M 913K 1.9% ▲ 226.7%
Bank Of America Corp $37.4M 901K 1.9% ▲ 55.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Omnicell, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $3M 11 trades by 3 insiders · 100% under pre-set plans
Net ▼ $3M net selling
Insider Date Trade Shares Price Value
Njoku Nnamdi President & COO August 17, 2026 Sell pre-set plan 3,083 $36.85 $113,609
Lipps Randall A CHAIRMAN, CEO July 15, 2026 Sell pre-set plan 10,000 $47.00 $470,000
Manley Corey J EVP&CHIEF LEGAL/ADMIN OFFICER May 18, 2026 Sell pre-set plan 5,025 $43.22 $217,180
Njoku Nnamdi EVP, Chief Operating Officer May 18, 2026 Sell pre-set plan 3,090 $43.22 $133,550
Manley Corey J EVP&CHIEF LEGAL/ADMIN OFFICER March 16, 2026 Sell pre-set plan 7,405 $34.69 $256,879
Manley Corey J EVP&CHIEF LEGAL/ADMIN OFFICER February 17, 2026 Sell pre-set plan 4,243 $36.59 $155,251
Manley Corey J EVP&CHIEF LEGAL/ADMIN OFFICER January 8, 2026 Sell pre-set plan 6,106 $49.90 $304,689
Manley Corey J EVP&CHIEF LEGAL/ADMIN OFFICER December 16, 2025 Sell pre-set plan 278 $43.30 $12,037
Manley Corey J EVP&CHIEF LEGAL/ADMIN OFFICER December 3, 2025 Sell pre-set plan 6,106 $39.90 $243,629
Lipps Randall A CHAIRMAN, PRESIDENT AND CEO December 1, 2025 Sell pre-set plan 28,250 $35.97 $1M
Manley Corey J EVP&CHIEF LEGAL/ADMIN OFFICER November 17, 2025 Sell pre-set plan 3,473 $34.90 $121,208

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Omnicell, Inc. disclosed in the last 12 months; 1 earlier trade on record.

  • Sara Jacobs(D-CA 53):Sale (full), $50,001 - $100,000, traded April 9, 2021, filed May 28, 2021

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around February 4, 2027 estimated from the company's past filing pattern, not announced

  • October 29, 2026
  • July 30, 2026
  • April 28, 2026
  • February 5, 2026
  • October 30, 2025
  • July 31, 2025

Recent SEC filings

Data status

When each part of this page on Omnicell, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Omnicell, Inc. in brief

What does Omnicell, Inc. do?
Omnicell, Inc. is a US-listed company in the health care technology industry. Its financial year ends in December.
What is Omnicell, Inc.'s stock ticker?
Omnicell, Inc. trades under the ticker OMCL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Omnicell, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Omnicell, Inc. reported revenue of $1.2B, 8.5% higher than a year earlier, according to its SEC filings.
What is Omnicell, Inc.'s free cash flow?
Omnicell, Inc.'s free-cash-flow margin is 11.4% of revenue over the trailing twelve months, ranking 10 of the 22 health care technology companies we cover.
What is Omnicell, Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Omnicell, Inc.'s free cash flow after stock-based pay gives ~$44 per share in the base case, and ~$33–$57 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Omnicell, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Portfolio Management LLC and Wellington Management Group LLP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Omnicell, Inc.'s market cap?
On November 2, 2026, Omnicell, Inc.'s market capitalisation was about $1.7B, with a price-to-earnings ratio of 42.9 and net debt of -$124M. Market figures come from third-party market data and may be delayed.
How much debt does Omnicell, Inc. have?
Omnicell, Inc.'s debt-to-equity ratio is 13.0%, from its latest balance sheet (0.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Omnicell, Inc.'s competitors?
In our Health Care Technology peer group, the companies closest to Omnicell, Inc. are Waystar Holding Corp., Tempus AI, Inc., Goodrx Holdings, Inc., Doximity, Inc. and Teladoc Health, Inc. The side-by-side comparison below sets their revenue, margins and growth against Omnicell, Inc.'s.
Are insiders buying or selling Omnicell, Inc. stock?
Over the last 12 months, Omnicell, Inc.'s directors and officers reported 0 open-market purchases and 11 sales on Form 4. The insider trading page charts every trade.
When is Omnicell, Inc.'s next earnings date?
Around February 4, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Omnicell, Inc. announces its own schedule.